PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $791,000 | -95.5% | 100,000 | -86.6% | 0.07% | -95.1% |
| Q1 2022 | $17,699,000 | -33.9% | 747,441 | -4.5% | 1.34% | -14.1% |
| Q4 2021 | $26,774,000 | +407.6% | 782,857 | +163.0% | 1.56% | +401.3% |
| Q3 2021 | $5,275,000 | -73.8% | 297,709 | -33.7% | 0.31% | -73.1% |
| Q2 2021 | $20,155,000 | +18.8% | 449,082 | -31.4% | 1.16% | +13.9% |
| Q1 2021 | $16,962,000 | +142.5% | 654,900 | +83.1% | 1.02% | +96.5% |
| Q3 2020 | $6,994,000 | +21.5% | 357,769 | +9.7% | 0.52% | +43.0% |
| Q2 2020 | $5,758,000 | – | 326,064 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |